Jennifer S Michaelson

Summary

Affiliation: Biogen Idec
Country: USA

Publications

  1. doi Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway
    Jennifer S Michaelson
    Biogen Idec, 12 Cambridge Center, Cambridge, MA 02142, USA
    Results Probl Cell Differ 49:145-60. 2009
  2. pmc Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR
    Jennifer S Michaelson
    Biogen Idec, Inc, Cambridge, MA 02142, USA
    MAbs 1:128-41. 2009
  3. ncbi The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models
    Jennifer S Michaelson
    Biogen Idec, Cambridge, MA, USA
    Cancer Biol Ther 13:812-21. 2012
  4. pmc Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study
    Noa Schwartz
    Division of Rheumatology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Arthritis Res Ther 11:R143. 2009
  5. ncbi Tweak induces mammary epithelial branching morphogenesis
    Jennifer S Michaelson
    Department of Exploratory Science, Biogen Idec, 12 Cambridge Center, Bio6 320, Cambridge MA, USA
    Oncogene 24:2613-24. 2005
  6. pmc Development of an Fn14 agonistic antibody as an anti-tumor agent
    Jennifer S Michaelson
    Molecular Discovery, Biogen Idec, 12 Cambridge Center, Cambridge, MA, USA
    MAbs 3:362-75. 2011
  7. pmc TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration
    Mahasweta Girgenrath
    Boston Biomedical Research Institute, Watertown, MA, USA
    EMBO J 25:5826-39. 2006
  8. ncbi TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease
    Linda C Burkly
    Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge, MA 02142, USA
    Cytokine 40:1-16. 2007
  9. doi Stability engineering of scFvs for the development of bispecific and multivalent antibodies
    Brian R Miller
    Biogen Idec, Inc, 5200 Research Place, San Diego, CA 92122, USA
    Protein Eng Des Sel 23:549-57. 2010
  10. pmc TWEAK induces liver progenitor cell proliferation
    Aniela Jakubowski
    Department of Exploratory Science, Biogen Idec Inc, Cambridge, Massachusetts 02142, USA
    J Clin Invest 115:2330-40. 2005

Collaborators

Detail Information

Publications24

  1. doi Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway
    Jennifer S Michaelson
    Biogen Idec, 12 Cambridge Center, Cambridge, MA 02142, USA
    Results Probl Cell Differ 49:145-60. 2009
    ....
  2. pmc Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR
    Jennifer S Michaelson
    Biogen Idec, Inc, Cambridge, MA 02142, USA
    MAbs 1:128-41. 2009
    ..These studies support that stability-engineering is an enabling step for producing scalable IgG-like BsAbs with properties desirable for biopharmaceutical development...
  3. ncbi The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models
    Jennifer S Michaelson
    Biogen Idec, Cambridge, MA, USA
    Cancer Biol Ther 13:812-21. 2012
    ..Taken together, the data presented herein suggest that BIIB036 warrants evaluation in the clinic...
  4. pmc Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study
    Noa Schwartz
    Division of Rheumatology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Arthritis Res Ther 11:R143. 2009
    ..Evidence for the importance of TWEAK in the pathogenesis of lupus nephritis (LN) has been recently introduced. Thus, TWEAK levels may serve as an indication of LN presence and activity...
  5. ncbi Tweak induces mammary epithelial branching morphogenesis
    Jennifer S Michaelson
    Department of Exploratory Science, Biogen Idec, 12 Cambridge Center, Bio6 320, Cambridge MA, USA
    Oncogene 24:2613-24. 2005
    ..Together, our results suggest that the Tweak/Fn14 pathway may be protumorigenic in human breast cancer...
  6. pmc Development of an Fn14 agonistic antibody as an anti-tumor agent
    Jennifer S Michaelson
    Molecular Discovery, Biogen Idec, 12 Cambridge Center, Cambridge, MA, USA
    MAbs 3:362-75. 2011
    ..Taken together, the anti-tumor properties of BIIB036 validate Fn14 as a promising target in oncology and demonstrate its potential therapeutic utility in multiple solid tumor indications...
  7. pmc TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration
    Mahasweta Girgenrath
    Boston Biomedical Research Institute, Watertown, MA, USA
    EMBO J 25:5826-39. 2006
    ....
  8. ncbi TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease
    Linda C Burkly
    Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge, MA 02142, USA
    Cytokine 40:1-16. 2007
    ..In addition to a perspective of the biology, we discuss potential therapeutic strategies targeting this pathway for the treatment of tissue injury, chronic inflammatory diseases and cancer...
  9. doi Stability engineering of scFvs for the development of bispecific and multivalent antibodies
    Brian R Miller
    Biogen Idec, Inc, 5200 Research Place, San Diego, CA 92122, USA
    Protein Eng Des Sel 23:549-57. 2010
    ..Introduction of a stability-engineered scFv as part of an IgG-like BsAb enabled scalable production and purification of BsAb with favorable biophysical properties...
  10. pmc TWEAK induces liver progenitor cell proliferation
    Aniela Jakubowski
    Department of Exploratory Science, Biogen Idec Inc, Cambridge, Massachusetts 02142, USA
    J Clin Invest 115:2330-40. 2005
    ..We conclude that TWEAK has a selective mitogenic effect for liver oval cells that distinguishes it from other previously described growth factors...
  11. doi TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses
    Linda C Burkly
    Immunology Discovery Research, Biogen Idec, Inc, Cambridge, MA 02142, USA
    Immunol Rev 244:99-114. 2011
    ..Whereas transient TWEAK/Fn14 activation promotes productive tissue responses after injury, excessive or persistent TWEAK/Fn14 activation drives pathological tissue responses, leading to progressive damage and degeneration...
  12. pmc Role of TWEAK in lupus nephritis: a bench-to-bedside review
    Jennifer S Michaelson
    Immunology Discovery Biology, Biogen Idec, Cambridge, MA 02142, USA
    J Autoimmun 39:130-42. 2012
    ..Taken together, targeting the TWEAK/Fn14 axis represents a potential new therapeutic paradigm for achieving renal protection in LN patients...
  13. doi TWEAK signals through JAK-STAT to induce tumor cell apoptosis
    Mark S Chapman
    Molecular Discovery, Biogen Idec, 12 Cambridge Center, Cambridge, MA 02142, United States
    Cytokine 61:210-7. 2013
    ..These findings may have implications for the appropriately targeted clinical development of Fn14 agonists as anti-cancer therapy...
  14. ncbi Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome
    Nhan L Tran
    Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Cancer Res 66:9535-42. 2006
    ..Such a feedback loop argues for aggressive targeting of the Fn14 axis as a unique and specific driver of glioma malignant behavior...
  15. ncbi Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells
    Sean Campbell
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Immunol 176:1889-98. 2006
    ..Our results support Ab inhibition of TWEAK as a potential new approach for the treatment of chemokine-dependent inflammatory kidney diseases...
  16. ncbi TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus
    Zeguo Zhao
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Immunol 179:7949-58. 2007
    ..Thus, TWEAK blockade may be a novel therapeutic approach to reduce renal damage in SLE...
  17. ncbi Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis
    Noa Schwartz
    Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Ann N Y Acad Sci 1109:265-74. 2007
    ..Additionally, we provide evidence for the possible utility of the novel cytokine TWEAK as a urinary biomarker for LN...
  18. ncbi Urinary TWEAK and the activity of lupus nephritis
    Noa Schwartz
    Division of Rheumatology, Forchheimer 701N, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    J Autoimmun 27:242-50. 2006
    ..An accurate, non-invasive method to repeatedly assess kidney disease in lupus would be very helpful in managing these often challenging patients. Our study indicates that urinary TWEAK levels may be useful as a novel biomarker in LN...
  19. ncbi Critical role for Daxx in regulating Mdm2
    Jun Tang
    Abramson Family Cancer Research Institute and Department of Cancer Biology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Nat Cell Biol 8:855-62. 2006
    ..These findings reveal that Daxx modulates the function of Mdm2 at multiple levels and suggest that the disruption of the Mdm2-Daxx interaction may be important for p53 activation in response to DNA damage...
  20. ncbi TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia
    Xiaohui Zhang
    Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Cereb Blood Flow Metab 27:534-44. 2007
    ..These findings show that the cytokine TWEAK plays a role in the disruption of the structure of the NVU during cerebral ischemia and that TWEAK antagonism is a potential therapeutic strategy for acute cerebral ischemia...
  21. ncbi Elucidation of a downstream boundary of the 3' IgH regulatory region
    John P Manis
    Howard Hughes Medical Institute, Children s Hospital, Harvard Medical School Boston, Enders Building, Room 861, 320 Longwood Avenue, Boston, MA 02115, USA
    Mol Immunol 39:753-60. 2003
    ..These findings, coupled with previous pgk-neo insertion studies, suggest that key elements of the 3' IgH RR lie within a 17kb region between HS1,2 and 2kb downstream of HS4...
  22. pmc Homeodomain-interacting protein kinase 1 modulates Daxx localization, phosphorylation, and transcriptional activity
    Jeffrey A Ecsedy
    Department of Genetics, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cell Biol 23:950-60. 2003
    ..Taken together, our results indicate that HIPK1 and Daxx collaborate in regulating transcription...
  23. ncbi Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently
    Isabelle Nefkens
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    J Cell Sci 116:513-24. 2003
    ..The fact that enzymatic activation of protein release or segregation after stress modifies the heat-shock response strengthens the concept of ND10 as a regulated depot of effector proteins...
  24. ncbi RNAi reveals anti-apoptotic and transcriptionally repressive activities of DAXX
    Jennifer S Michaelson
    Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Cell Sci 116:345-52. 2003
    ..Thus, depletion of DAXX by RNAi has verified the crucial role of endogenous DAXX as an anti-apoptotic regulator, and has allowed the identification of probable physiological targets of DAXX transcriptional repression...